Furthermore, the stimulation of 5-HT2AR/D2R heteromers with D2R agonists has been shown to be suppressed by the co-administration of 5-HT2A-agonists, indicating a 5-HT2AR-mediated trans-inhibition of D2Rs [136] and suggesting to explore this heteromer as a potential target for new therapeutic strategies for schizophrenia treatment. This evidence concerns the gene DRD2 and schizophrenia.